Boston Scientific Beats Q1 Earnings as Cardiovascular Sales Surge 13.5%
Boston Scientific (NYSE: BSX) delivered first-quarter earnings of $0.80 per share on an adjusted basis, meeting the high end of guidance and climbing 6.7% from $0.75 in the prior year. The medical device giant posted revenue of $5.203 billion, up 11.6% year-over-year and within the company's guidance range of 10.5% to 12.0% growth.
Key Numbers
The headline number that stands out: Cardiovascular segment sales surged 13.5% to $3.503 billion, accounting for over two-thirds of total revenue and significantly outpacing the MedSurg division's 7.8% growth to $1.701 billion. On an organic basis, which strips out currency impacts, total company growth came in at 9.4%, near the top of the 8.5% to 10.0% guidance range.
GAAP earnings told an even more impressive story, with net income attributable to common stockholders doubling to $1.341 billion, or $0.90 per share, compared to $674 million, or $0.45 per share a year ago. This dramatic improvement reflects both operational strength and favorable comparisons.
Geographically, Boston Scientific demonstrated balanced global growth. The U.S. market, representing 63% of sales, grew 10.9%. International markets showed particular strength in Latin America and Canada (up 19.0% reported, 12.0% operational) and Asia-Pacific (up 14.7% reported, 12.0% operational). Europe, Middle East and Africa grew 10.1% on a reported basis but just 1.2% operationally after currency headwinds.
Within the MedSurg segment, Neuromodulation led with 17.4% growth to $318 million, followed by Endoscopy at 9.4% growth to $736 million. Urology lagged with just 2.1% growth to $646 million.
What Management Said
CEO Mike Mahoney struck a confident but measured tone, attributing the quarter's performance to "the strength of our category leadership strategy" while emphasizing the company's focus on "executing our long-term strategy and advancing our differentiated pipeline."
Management's forward guidance suggests continued momentum but at a more moderate pace. For the full year 2026, Boston Scientific now expects reported revenue growth of 7.0% to 8.5% (organic growth of 6.5% to 8.0%), with adjusted EPS of $3.34 to $3.41. This implies a meaningful deceleration from Q1's double-digit growth rate.
For Q2 2026, the company guided to 5.5% to 7.5% reported revenue growth (5.0% to 7.0% organic) with adjusted EPS of $0.82 to $0.84. The sequential slowdown in growth expectations likely reflects tougher comparisons and conservative positioning given macro uncertainties.
The company highlighted several major clinical trial wins during the quarter, particularly the CHAMPION-AF study for its WATCHMAN FLX device and the ADVENT Long-Term Outcomes trial for its FARAPULSE Pulsed Field Ablation system. These positive outcomes strengthen Boston Scientific's competitive position in high-growth cardiac markets.
What to Watch
The cardiovascular franchise remains the key growth engine and bears watching closely. At current run rates, this segment alone generates over $14 billion annually and its 11.2% organic growth rate significantly outpaces overall company growth. The recent clinical trial successes in atrial fibrillation treatment (WATCHMAN FLX and FARAPULSE) position the company well for continued share gains.
Investors should monitor the pace of growth deceleration through 2026. Management's guidance implies Q2 organic growth could dip below 6% at the midpoint, less than half of Q1's 11.2% cardiovascular organic growth. Whether this proves conservative or signals genuine headwinds will become clearer as the year progresses.
The Urology business's anemic 0.5% operational growth stands out as an area needing improvement. The recent acquisition of Valencia Technologies and its eCoin System for urinary incontinence suggests management recognizes this weakness and is taking steps to reinvigorate the franchise.
International markets present both opportunity and risk. While Latin America and Asia-Pacific showed robust double-digit operational growth, the EMEA region's 1.2% operational growth reveals continued challenges in Europe. Currency headwinds shaved 2.2% off reported growth in Q1, and further dollar strength could pressure results.
Finally, the company's ability to sustain margins while investing in R&D and navigating supply chain challenges will be critical. The adjusted EPS growth of 6.7% year-over-year on 9.4% organic revenue growth suggests modest margin pressure, though the GAAP earnings surge indicates strong underlying profitability.
Boston Scientific's Q1 results demonstrate the company's strong competitive position in cardiovascular devices and its ability to drive consistent growth across most segments. While growth is set to moderate, the clinical pipeline and recent product launches provide multiple catalysts for sustained outperformance in key therapeutic areas.
*Source: Boston Scientific Q1 2026 Earnings Release, SEC Filing*
— StockCliff Research